Stemline Therapeutics Inc. (STML) Rating Increased to Buy at Zacks Investment Research
Stemline Therapeutics Inc. (NASDAQ:STML) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. The brokerage presently has a $12.00 target price on the biopharmaceutical company’s stock. Zacks Investment Research’s target price would suggest a potential upside of 9.79% from the company’s previous close.
According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “
Several other research analysts also recently commented on STML. Roth Capital reaffirmed a “buy” rating and issued a $32.00 price target on shares of Stemline Therapeutics in a research note on Thursday, June 9th. Wedbush reaffirmed an “outperform” rating and issued a $16.00 price target on shares of Stemline Therapeutics in a research note on Tuesday, June 7th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Stemline Therapeutics in a research note on Friday, August 5th. Six analysts have rated the stock with a buy rating, Stemline Therapeutics has a consensus rating of “Buy” and a consensus target price of $20.50.
Stemline Therapeutics (NASDAQ:STML) opened at 10.93 on Wednesday. The stock has a 50 day moving average of $9.27 and a 200 day moving average of $7.17. The company’s market cap is $194.83 million. Stemline Therapeutics has a 52 week low of $3.88 and a 52 week high of $11.29.
Stemline Therapeutics (NASDAQ:STML) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.03. Stemline Therapeutics had a negative net margin of 4,419.18% and a negative return on equity of 44.59%. On average, analysts expect that Stemline Therapeutics will post ($2.11) earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Investment Management LLC increased its position in Stemline Therapeutics by 13.1% in the second quarter. BlackRock Investment Management LLC now owns 66,093 shares of the biopharmaceutical company’s stock worth $447,000 after buying an additional 7,676 shares during the period. Vanguard Group Inc. increased its position in Stemline Therapeutics by 3.9% in the second quarter. Vanguard Group Inc. now owns 526,691 shares of the biopharmaceutical company’s stock worth $3,566,000 after buying an additional 19,877 shares during the period. Dimensional Fund Advisors LP increased its position in Stemline Therapeutics by 133.9% in the second quarter. Dimensional Fund Advisors LP now owns 34,337 shares of the biopharmaceutical company’s stock worth $232,000 after buying an additional 19,658 shares during the period. Nationwide Fund Advisors increased its position in Stemline Therapeutics by 63.2% in the second quarter. Nationwide Fund Advisors now owns 22,395 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 8,670 shares during the period. Finally, Emerald Acquisition Ltd. acquired a new position in Stemline Therapeutics during the second quarter worth approximately $129,000. 52.42% of the stock is currently owned by institutional investors and hedge funds.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.